As FGF23 levels are elevated in XLH patients and further stimulated by treatment with phosphate supplements and active vitamin D, interest in the cardiovascular risk profile of XLH patients arose [14]. This evidence concerns the gene FGF23 and X-linked hypophosphatemia.